Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular PCA3 diagnostics on prostatic fluid.

Martijn P M Q van Gils1, Erik B Cornel, Daphne Hessels

  • 1Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

The Prostate
|April 19, 2007
PubMed
Summary

The PCA3 test, used for prostate cancer (PCa) diagnosis, shows comparable results whether performed on urine or prostatic fluid. This diagnostic tool can help avoid unnecessary prostate biopsies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What's next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same author

Explainable and likelihood aware AI framework for MRI-based pixel-level bladder tumour prediction.

Scientific reports·2025
Same author

Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.

European urology·2025
Same author

Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer.

BJUI compass·2025
Same author

Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.

European urology·2025
Same author

Letter: Updates to Microhematuria: AUA/SUFU Guideline (2025).

The Journal of urology·2025

Area of Science:

  • Urology
  • Oncology
  • Molecular Diagnostics

Background:

  • Prostate cancer (PCa) diagnosis can be improved with the PCA3 test on urine, potentially reducing unnecessary biopsies.
  • This study investigates the utility of the PCA3 test on prostatic fluid compared to urine in a clinical research setting.

Purpose of the Study:

  • To evaluate the performance of the PCA3 test on prostatic fluid for prostate cancer detection.
  • To compare the diagnostic accuracy of the PCA3 test on prostatic fluid versus urine.

Main Methods:

  • Prostatic fluid and urine samples were collected from 67 men after digital rectal examination (DRE).
  • Quantitative APTIMA PCA3 test was performed on sample sediments.
  • Results were correlated with prostate biopsy outcomes.

Related Experiment Videos

Main Results:

  • The PCA3 test on prostatic fluid achieved 65% sensitivity and 82% specificity at a cut-off score of 66.
  • The PCA3 test on urine showed 61% sensitivity and 80% specificity at a cut-off score of 43.
  • Both tests demonstrated comparable diagnostic performance.

Conclusions:

  • The PCA3 test is a viable option for prostate cancer diagnosis using either urine or prostatic fluid.
  • Comparable results suggest flexibility in sample type for PCA3 testing in PCa diagnosis.